SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

External view of Bristol Myers Squibb's office California
Earnings
BMS Gets Q2 Beat, Raises Full-Year Guidance as Cost-Cutting Initiative Continues
Bristol Myers Squibb on Friday reported strong second-quarter results, led by the blood thinner Eliquis and cancer therapy Opdivo, as it looks to cut $1.5 billion in costs by 2025.
July 26, 2024
 · 
2 min read
 · 
Tristan Manalac
Roche's tower in Shanghai, China
Weight loss
Roche to Accelerate Development of Obesity Assets from $2.7B Carmot Buy
Encouraged by the potential of the weight-loss candidates acquired from Carmot Therapeutics, Roche will speed up the development of its obesity programs, seeking to differentiate itself in the market.
July 26, 2024
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
Adcomms
FDA Adcomm Calls for Changes in Perioperative Lung Cancer Trials
The FDA’s Oncologic Drugs Advisory Committee on Thursday strongly supported changing clinical trials for non-small cell lung cancer drugs given in the perioperative setting, pointing out the need for a more nuanced approached to treatments before and after surgery.
July 26, 2024
 · 
2 min read
 · 
Tristan Manalac
A group of businessmen discussing financial reports
Earnings
Argenx’s Strong Q2 Sales Reinvigorate Clinical Plans for Vyvgart
The company’s FcRn inhibitor Vyvgart grew 17% quarter-over-quarter, reigniting confidence it will hit its ambitious goals despite a string of clinical setbacks in recent months.
July 26, 2024
 · 
2 min read
 · 
Tristan Manalac
Concept illustration showing two hands exchanging a dollar sign for a lightbulb
Earnings
AstraZeneca, Roche, Sanofi Raise 2024 Outlooks on Strong Q2 Sales
The three companies raised their respective full-year earnings forecasts on Thursday, buoyed by robust sales in the second quarter and their continued dominant market positions.
July 25, 2024
 · 
3 min read
 · 
Tristan Manalac
Photo of a GLP-1 injector pen on a blue background
GLP-1
Viking Takes Obesity Candidate into Phase III to Rival Lilly, Novo
With promising Phase II data in hand, Viking Therapeutics is pushing its subcutaneous GLP-1/GIP receptor dual agonist into late-stage development, the company announced on Wednesday.
July 25, 2024
 · 
2 min read
 · 
Tristan Manalac
External view of Novartis' office in Massachusetts
Collaboration
Novartis, Dren Bio Ink Potential $3B Deal for Anti-Myeloid Bispecific Antibodies for Cancer
Novartis continues its dealmaking spree with a bet on Dren Bio’s Targeted Myeloid Engager and Phagocytosis platform to develop bispecific antibodies in oncology.
July 25, 2024
 · 
2 min read
 · 
Tristan Manalac
FDA sign outside its office in Maryland
Regulatory
FDA Issues Final Guidance for Using Real-World Data in Drug Applications
The regulator on Wednesday provided recommendations to drugmakers for assessing the use of electronic health records and medical claims data to support their applications.
July 25, 2024
 · 
2 min read
 · 
Tristan Manalac
Hand shaking while holding a glass
Clinical research
Biogen, Sage Scrap Essential Tremor Study After Phase II Failure
Biogen and Sage Therapeutics’ investigational neuroactive steroid did not significantly improve upper limb tremors in patients with essential tremor, the companies announced Wednesday.
July 24, 2024
 · 
2 min read
 · 
Tristan Manalac
External view of AstraZeneca's headquarters building in Silicon Valley
Adcomms
FDA Flags Potential ‘Overtreatment’ for NSCLC With AstraZeneca’s Imfinzi Ahead of Adcomm
AstraZeneca is proposing to use Imfinzi for resectable non-small cell lung cancer in the perioperative setting—both before and after surgical resection of the tumor. However, ahead of Thursday’s advisory committee meeting, FDA staffers have expressed concerns.
July 24, 2024
 · 
2 min read
 · 
Tristan Manalac
External view of the U.S. Capitol Building
Pharmacy benefit managers
PBM Execs Point Fingers at Pharma Industry in House Hearing on Rising Drug Prices
Executives from the three largest pharmacy benefit manager companies testified Tuesday before Congress that rising drug prices in the U.S. are due to pharma companies taking advantage of market exclusivities and excessive charges.
July 24, 2024
 · 
2 min read
 · 
Tristan Manalac
A 3D illustration of an antibody binding to human cell receptors
Series A
J&J Alums Raise $165M Series A for Startup to Develop Biologics for Cancer, Autoimmune Diseases
Third Arc Bio, led by three former Johnson & Johnson executives, is advancing a portfolio of multifunctional antibodies for cancer and inflammatory and immune-mediated diseases.
July 24, 2024
 · 
2 min read
 · 
Tristan Manalac
Merck Research Laboratories in South San Francisco, California
RSV
Merck Challenges AstraZeneca, Sanofi With Phase IIb/III Data for RSV Antibody
Merck’s clesrovimab lowered the risk of medically attended lower respiratory infections associated with RSV infection when used in infants, according to topline results announced Tuesday.
July 23, 2024
 · 
2 min read
 · 
Tristan Manalac
Agilent's signage at its office in California
Mergers & acquisitions
Agilent Pays $925M to Buy CDMO Biovectra to Boost Biologics, CRISPR Capabilities
The acquisition of the contract development and manufacturing organization will allow Agilent Technologies to provide a one-stop source for gene-editing services for its customers.
July 23, 2024
 · 
2 min read
 · 
Tristan Manalac
External view of the U.S. Securities and Exchange Commission in Washington, DC
Regulatory
SEC Hits Allarity With Wells Notice, Flags Alleged Violations in FDA Meeting
Allarity Therapeutics announced Monday that the Securities and Exchange Commission has made a preliminary determination recommending an enforcement action against the company for alleged violations of federal securities laws.
July 23, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More